Predicting migraine attack pain using wearable devices

Prediction Study of the Pain Phase of Migraine Attacks in Patients With Episodic Migraine

Observational Fundación de Investigación Biomédica - Hospital Universitario de La Princesa · NCT06459635

This study is testing if a wearable device can help people with episodic migraines predict when their attacks will start by tracking their body signals.

Quick facts

Study typeObservational
Enrollment70 (estimated)
Ages18 Years to 65 Years
SexAll
SponsorFundación de Investigación Biomédica - Hospital Universitario de La Princesa Academic / other
Locations1 site (Madrid)
Trial IDNCT06459635 on ClinicalTrials.gov

What this trial studies

This observational study aims to predict the onset of migraine attacks by monitoring patients' hemodynamic variables through a wearable device. Patients with episodic migraine will be recruited from specialized headache clinics and will track their migraine characteristics over a two-month period. The data collected will be used to develop individualized algorithms for predicting migraine attacks based on premonitory symptoms. This research is part of a long-term initiative by the Headaches Unit at Hospital de La Princesa in collaboration with local universities.

Who should consider this trial

Good fit: Ideal candidates are individuals aged 15 to 69 with a diagnosis of high-frequency episodic migraine and the ability to use smartphone technology.

Not a fit: Patients with other types of headaches or cognitive impairments that hinder participation may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could enable patients to anticipate migraine attacks and manage their symptoms more effectively.

How similar studies have performed: Previous studies have shown promise in using wearable technology for headache prediction, indicating a potential for success in this approach.

Eligibility criteria

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Age between 15 years and 69 years.
* Diagnosed with migraine by a headache neurologist and according to the criteria proposed by ICHD-3.
* History of migraine of at least 1 year of evolution.
* Normal neurological examination.
* Have given your informed consent.
* Be able to describe your clinical situation and the characteristics of your headache.
* Have an average of 10 to 14 migraine days per month in the three months prior to inclusion (high-frequency episodic migraine).
* User-level management capacity of "smartphone" type electronic devices.
* Be able to complete two months of study follow-up.

Exclusion Criteria:

* Presence of another type of headache, with the exception of headache due to excessive use of analgesic medication.
* Cognitive deficiency or any other pathology that may prevent or make it difficult for the patient to perform the study correctly.
* Neurological focus in the examination.
* Pregnancy or breastfeeding period.
* Patients with known heart disease or bronchopathy, Sjögren\'s syndrome, diabetes mellitus, or hypo/hyperthyroidism.
* Carriers of pacemakers, neurostimulators or any other electronic device that is considered to make the interpretation of biometric records difficult.
* Anatomical problem that makes the use of the device impossible.
* Patients in whom it is expected that a change in migraine preventive treatment or other usual treatment will be possible during the study period.

Where this trial is running

Madrid

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions MigraineMigraine HeadacheMigraine DisordersMigraine Without AuraMigraine With AuraHeadachePredictPrediction
Last reviewed 2026-06-09 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.